Latest Breaking News On - Polycythemia vera - Page 1 : comparemela.com

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 RE

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Associatio.

Ann arborUnited statesHall goyaKristenm pettitCorey davisDivision of hematology oncologyDepartment of internal medicineNetwork of companiesUniversity of michiganEuropean hematology associationProtagonist therapeutics incProtagonist therapeuticsPresentation titleUpdated long term resultsStudy investigatingHepcidin mimetic rusfertide

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

United statesAnn arborHall goyaKristenm pettitCorey davisUniversity of michiganVirginia amannentente network of companiesDepartment of internal medicineDivision of hematology oncologyNews networkProtagonist therapeutics incEuropean hematology associationProtagonist therapeuticsOral presentation titleUpdated long term resultsStudy investigating

Protagonist Therapeutics, Inc : Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics, Inc : Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesAnn arborHall goyaKristenm pettitCorey davisDepartment of internal medicineDivision of hematology oncologyProtagonist therapeutics incUniversity of michiganEuropean hematology associationNetwork of companiesProtagonist therapeuticsPresentation titleUpdated long term resultsStudy investigatingHepcidin mimetic rusfertide

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

United statesAnn arborKristenm pettitCorey davisHall goyaProtagonist therapeutics incEuropean hematology associationUniversity of michiganDivision of hematology oncologyDepartment of internal medicineNetwork of companiesProtagonist therapeuticsPresentation titleUpdated long term resultsStudy investigatingHepcidin mimetic rusfertide

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSteven steinEuropean hematology associationEuropean medicines agencyMyeloproliferative neoplasms biology translational researchDrug administrationExchange commissionIncyte corporationAmerican society of clinical oncologyMyeloproliferative neoplasms biology transitional researchXencor incLymphoma biology translational researchClinical oncologyAnnual meetingChief medical officerSelect advanced solid tumors